Last $16.69 USD
Change Today -0.05 / -0.30%
Volume 4.1K
RDSMY On Other Exchanges
EN Amsterdam
As of 11:32 AM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

koninklijke dsm nv-spons adr (RDSMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/19/13 - $20.34
52 Week Low
02/27/14 - $15.67
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

koninklijke dsm nv-spons adr (RDSMY) Related Businessweek News

View More BusinessWeek News

koninklijke dsm nv-spons adr (RDSMY) Details

Koninklijke DSM N.V. operates as a life sciences and materials sciences company worldwide. The company operates in five segments: Nutrition, Pharma, Performance Materials, Polymer Intermediates, and Innovation Center. It manufactures food enzymes, cultures, savory ingredients, and other specialties, as well as nutritional products, such as vitamins, carotenoids, eubiotics, feed enzymes, premixes, nutritional lipids, and cultures for the food and beverage, feed, personal care, dietary supplements, and pharmaceutical industries. The company also provides custom manufacturing and development services to the pharmaceutical, biopharmaceutical, and agrochemical industries; and beta-lactam active pharmaceutical ingredients, such as semi-synthetic penicillins and semi-synthetic cephalosporins, as well as nystatin. In addition, it offers engineering thermoplastic solutions; Dyneema, a strong fiber; and resins solutions for paints and coatings, composite materials, and optical fiber coatings. Further, the company produces caprolactam and acrylonitrile that are raw materials for synthetic fibers and plastics; and other products, including ammonium sulfate, sodium cyanide, cyclohexanone, and diaminobutane. Additionally, it develops materials-based solutions comprising coatings, drug delivery platforms, and a range of biomedical materials for medical device and biopharmaceutical industries; creates solutions for bioconversion of feedstocks for the production of bio-energy, such as cellulosic biofuels, as well as bio-based chemicals and materials; and provides smart coatings and surface technologies to the solar industry. The company was founded in 1902 and is headquartered in Heerlen, the Netherlands.

21,453 Employees
Last Reported Date: 08/5/14
Founded in 1902

koninklijke dsm nv-spons adr (RDSMY) Top Compensated Officers

Chairman of Managing Board, Chief Executive O...
Total Annual Compensation: €1.4M
Chief Financial Officer and Member of the Man...
Total Annual Compensation: €902.0K
Member of The Managing Board
Total Annual Compensation: €954.0K
Member of Managing Board
Total Annual Compensation: €887.0K
Member of The Managing Board
Total Annual Compensation: €268.0K
Compensation as of Fiscal Year 2013.

koninklijke dsm nv-spons adr (RDSMY) Key Developments

Koninklijke DSM N.V. Launches Cellular Therapy Development Services

Koninklijke DSM N.V. launched its cellular therapy development services. Cellular therapies use a patient's own cells to improve healing of an injury or disease. DSM develops products that are distributed by major biotechnology and medical device companies into the hands of qualified physicians, who are ultimately responsible for patient care. DSM offers a complete package of design, development and manufacturing services to create cellular therapy products that are clinically valuable and commercially viable. The first product, developed by DSM and launched by DePuy Synthes Mitek Sports Medicine, concentrates platelets from whole blood in only two and a half minutes. The DePuy Synthes Mitek Sports Medicine PEAK Platelet Rich Plasma System yields a higher concentration of undamaged platelets and a more consistent output than existing devices on the market. Further, the device weighs only four pounds, making it easy to store in surgical specialty rooms as well as transport through a doctor's office or hospital.

Koninklijke DSM N.V., Board Meeting, Jul 28, 2014

Koninklijke DSM N.V., Board Meeting, Jul 28, 2014. Agenda: To approve portfolio manager changes.

Koninklijke DSM N.V. Reports Earnings Results for the Second Quarter of 2014; Provides Earnings Guidance for the Year 2014

Koninklijke DSM N.V. reported earnings results for the second quarter of 2014. For the quarter, the company reported EBITDA from continuing operations of EUR 293 million compared to EUR 332 million in second quarter of 2013. Net profit from continuing operations before exceptional items amounted to EUR 110 million compared to EUR 137 million in second quarter of 2013. Net earnings per ordinary share (continuing operations, before exceptional items) amounted to EUR 0.64 compared to EUR 0.80 in second quarter of 2013. Cash provided by operating activities was EUR 126 million compared to EUR 251 million in second quarter of 2013. Cash used for capital expenditure amounted to EUR 117 million compared to EUR 148 million in second quarter of 2013. Net debt increased by EUR 552 million compared to year-end 2013 and stood at EUR 2,393 million. DSM targets for 2014 to deliver an improved underlying business performance in a challenging macro environment. DSM is on track to meet current market expectations, notwithstanding the adverse impact from foreign exchange rates of about EUR 70 million and weakness in the caprolactam supply-chain.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDSMY:US $16.69 USD -0.05

RDSMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grupo Bimbo SAB de CV $40.26 MXN -0.20
Huntsman Corp $26.73 USD -0.16
LANXESS AG €46.51 EUR -0.29
Merck KGaA €66.18 EUR -0.16
Solvay SA €117.25 EUR +0.25
View Industry Companies

Industry Analysis


Industry Average

Valuation RDSMY Industry Range
Price/Earnings 56.6x
Price/Sales 0.9x
Price/Book 1.5x
Price/Cash Flow 40.9x
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KONINKLIJKE DSM NV-SPONS ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at